Cronexitide Lanocianine Drug Asset Due Diligence Report 2026

This Cronexitide Lanocianine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Cronexitide Lanocianine can convert its Contrast agent, Fluorescent Peptide, Cyclic Peptide profile and ANXA2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Cronexitide Lanocianine (query alias: Cronexitide Lanocianine)
Modality / target	Contrast agent, Fluorescent Peptide, Cyclic Peptide; ANXA2; ANXA2 inhibitors
Highest global status	Phase 2
Originator	Integro Theranostics LLC, Washington University in St. Louis
Active developers	Washington University in St. Louis, Guangdong Jidai Gene Drug Eng Research Ctr Co. Ltd., Wenzhou Medical College

The MCP disease footprint includes Corneal epithelial defect, Solid tumor. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
CTR20262391	Phase 2	Not yet recruiting	108	Primary endpoint not disclosed in English source
NCT04105062	Phase 1/2	Withdrawn	0	Primary endpoint not disclosed in English source
NCT02807597	Phase 1/2	Terminated	9	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evaluation of LS301 Uptake in Tumors of Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy for Breast Cancer

Phase 1/2; n=9; evaluation: Not stated in English source. Reported fields: Number of Participants With Related Adverse Events of LS301 in Breast (Phase I) = 0 Pts ; Number of Participants With Related Adverse Events of LS301 in Breast (Phase I) = 0 Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Cronexitide Lanocianine addresses Corneal epithelial defect, Solid tumor. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Contrast agent, Fluorescent Peptide, Cyclic Peptide—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned matched transaction record(s) under the scope “target-level comparable: ANXA2.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: ANXA2 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
No matched asset or comparable transaction returned.

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Near Infrared Fluorescent Dyes, Formulations and Related Methods”. The milestone feed surfaced a patent-application signal described as “Methods for detecting and treating joint disease”. The milestone feed surfaced a patent-application signal described as “Near infrared fluorescent DYES, formulations and related methods”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO